Cell Research第三次聚焦m6A修饰与成体造血干细胞调控

2018-08-30 BioArt BioArt

造血干细胞(HSCs)具有独特的自我更新能力,可以补充整个血液系统,其应对各种压力条件的能力至关重要,如连续移植、电离辐射、抗癌药物、出血或感染。N6-甲基腺嘌呤(m6A)是真核生物细胞中mRNA最普遍的可逆核苷酸修饰,与蛋白质编码转录物的成熟,翻译和最终衰变有关。 m6A修饰的“Reader”蛋白通过与甲基特异性RNA结合介导m6A-甲基化的转录。虽然最近已报道了m6A修饰在胚胎干细胞和造血干细

造血干细胞(HSCs)具有独特的自我更新能力,可以补充整个血液系统,其应对各种压力条件的能力至关重要,如连续移植、电离辐射、抗癌药物、出血或感染。N6-甲基腺嘌呤(m6A)是真核生物细胞中mRNA最普遍的可逆核苷酸修饰,与蛋白质编码转录物的成熟,翻译和最终衰变有关。 m6A修饰的“Reader”蛋白通过与甲基特异性RNA结合介导m6A-甲基化的转录。虽然最近已报道了m6A修饰在胚胎干细胞和造血干细胞和祖细胞(HSPCs)的细胞命运决定中的功能,但尚未报道“Reader”蛋白在HSC功能中的作用,特别是在造血应激下。

Cell Research在线发表了暨南大学/杭州师范大学鞠振宇、汪虎团队与南京医科大学沈彬研究组合作的题为Loss of YTHDF2-mediated m6A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration的最新研究成果。该工作阐明了m6A修饰的“Reader”YTHDF2蛋白在HSC稳态和各种应激下的再生机制及关键作用。

研究利用Mx1-Cre, Ert-Cre and Vav-Cre 的YTHDF2的特异性敲除小鼠,鉴定了YTHDF2介导的m6A识别在小鼠成体HSC中的独特功能。从机理上讲,YTHDF2在HSC中的表达促进了Wnt靶基因的m6A修饰的mRNA的衰变,有助于在稳态下抑制Wnt信号传导。但在敲除YTHDF2后,不仅扩增了HSC的数量,而且在应激条件下HSC的再生能力也增加了。通过研究数据表明,YTHDF2缺失同时阻止了造血应激下Wnt靶基因和抗凋亡相关基因的mRNA的降解,并且这种组合效应协同增强了HSC的再生能力。而前不久,李凌衡研究组的工作表明,Ythdf2能够特异性识别参与HSC自我更新功能的数十个关键转录因子mRNA(如Tal1,Gata2等)上的m6A位点,并导致这些mRNA的降解。如果在小鼠HSC中特异性敲除Ythdf2,使得这些重要的转录因子的mRNA稳定性增加,进而上调了HSC的自我更新能力。两个工作在结论上大同小异,互相印证,但是内容上的丰富程度有一定的差异。

造血再生的治疗是刺激干细胞增殖以立即进行组织修复,同时避免在应激下干细胞耗竭。此研究的结果揭示了YTHDF2介导的RNA m6A修饰的功能的重要性。 YTHDF2缺失促进了HSC扩增而不会在压力条件下丧失其生存能力。这些发现确定了YTHDF2在调节HSC的自我更新和再生中的关键作用,从这些结果中,也为其有效的转为临床应用提供了可能性。

值得一提的是,该文章是继今年7月15日周波研究组报道m6A甲基转移酶Mettl3–Mettl14 对成体造血干细胞的调控作用(Cell Res丨周波/龚玉萍合作组首次揭示m6A修饰对成体造血干细胞的调控作用)以及本月初李凌衡研究组报道m6A阅读器蛋白YTHDF2对成体造血干细胞的扩增作用以来Cell Research发表的第三篇m6A修饰与成体造血干细胞调控相关的文章,而且李凌衡组与鞠振宇组的共同聚焦到m6A阅读器蛋白YTHDF2。另外,7月25日,Cell Research还报道了中山大学崔隽组关于m6A调控自噬工作。

谈一点不算题外的题外话。m6A修饰领域近期可能还会热门一段时间,但是从发文章的角度来讲日后发表到CNS正刊上相对较难了。一个有趣的现象是,从最近刚刚公布了国家自然科学基金项目的数据来看,申请书的标题中包含m6A的项目超过了60项,其中绝大部分都是研究m6A与各类肿瘤的发生发展关系(BioArt近期将会陆续推出相关国自然项目的解读,尽请关注)。

据悉,鞠振宇教授、汪虎副教授、沈彬教授为本文的共同通讯作者,汪虎、左洪娜为论文的共同第一作者。

原始出处:
Wang H, Zuo H, Liu J, et al.Loss of YTHDF2-mediated m6A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration.Cell Res. 2018 Aug 27. doi: 10.1038/s41422-018-0082-y. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2019-02-02 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2019-07-16 kcb077
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2018-09-01 俅侠
  6. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2018-09-01 yangshch
  7. [GetPortalCommentsPageByObjectIdResponse(id=1961101, encodeId=3465196110179, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 21:18:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870831, encodeId=6d8d18e08313b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue May 28 04:18:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647768, encodeId=9d17164e76801, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Tue Jul 16 11:18:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271467, encodeId=55f412e1467fc, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494642, encodeId=77dd149464204, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557783, encodeId=df58155e7831c, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569329, encodeId=20f11569329f6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 01 00:18:00 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2018-09-01 zhangyxzsh

相关资讯

Cell Discov:复旦、浙大团队分别发文报道m6A调控新机制——杨运桂点评

过去的六七年间,对于真核生物mRNA上最为广泛的修饰m6A来说,围绕该修饰的一系列甲基化转移酶复合物、去甲基化转移酶和识别蛋白以及相关的生物学功能来说已经研究得相对较为透彻,然而这类研究多数还只是停留展示可调控m6A修饰水平变化,并没有回答m6A修饰如何实现位点选择性的分子机制。近日,来自复旦大学、浙江大学以及芝加哥大学等单位相继发表的两篇论文为深入研究以m6A修饰为核心的表观转录组学特征和规律奠

NATURE:我国科学家揭示m6A调控造血干细胞命运决定新机制”

血液,是生命的源泉。不断流动的血细胞既可以运输营养物质,又起到免疫保护作用。在发育过程中,所有的血细胞都来源于胚胎期产生的造血干细胞。随后,这些干细胞会迁移至成体骨髓以维持终身造血,此外,它们也是骨髓移植术治疗恶性血液疾病的核心组分。但在临床上,造血干细胞来源匮乏一直是制约血液疾病治疗的瓶颈。因此,探索造血干细胞的体内发育机制以及建立体外诱导扩增方案便成为当今科学界的研究热点。目前,人们对于造血干

Cell Res:m6A RNA修饰在哺乳动物精子发生中的作用及其机制

Cell Research 在线发表了中国科学院上海生科院生物化学与细胞生物学研究所童明汉研究组的研究成果“Mettl3/Mettl14-mediated mRNA N6-methyladenosine modulates murine spermatogenesis”。该研究绘制了小鼠不同发育阶段生精细胞的m6A RNA修饰图谱,揭示了m6A RNA修饰通过调控精子发生过程中关键基因的转录后翻译

Cell Res:重大进展,上海生科院携手四川大学揭示m6A在造血干细胞的作用

2018年7月13日,中国科学院上海生命科学研究院生化与细胞所周波研究组与四川大学龚玉萍研究组合作在Cell Research在线发表题为“Mettl3–Mettl14 methyltransferase complex regulates the quiescence of adult hematopoietic stem cells”的研究论文,该论文提供了证据表明Mettl3是成人骨髓中HS